Here we are again, less than 4 weeks to #ESMO26 - if feels like this year is flying! @myESMO Had a chance to go through the #GI program and LBA titles just released - abstracts to be released on October 19th 👀 ➡️lots to watch for - especially busy in the Upper GI space. 👇my top abstracts picks below - I'm still old school so without the benefit of ChatGPT...pls let me know what I missed! See you in #Madrid 👋

Highlighting upcoming #ESMO26 GU schedule in Madrid 📆 & looking forward to: 1) BLADDER: -TROPHY-U01 SG + EV/ZIM in 1L mUC -ctDNA from EV304 -LBA VOLGA: peri-op durva/EV +/- treme (➕ press release for EFS & OS) 2) RARE GU: -NAT toripalimab in penile CA -Claudin-6 ADC in GCT

My Top 10 Breast Cancer Abstracts #ESMO26 👇

🚨 ESMO 2026: 15 Trials That Could Change Oncology Practice! From personalized cancer vaccines and bispecific antibodies to next-generation ADCs, major results are coming. 🔥 My Top 15 to Watch: 1. INTerpath-001 | Melanoma 2. SAFFRON | EGFR+ NSCLC 3. Krascendo 1 | KRAS G12C NSCLC 4. DeLLphi-305 | ES-SCLC 5. HARMONi-GI1 | Biliary 6. VOLGA | Bladder 7. DASL-HiCaP | Prostate 8. NATALEE | Breast 9. TRIO-US B-12 TALENT | Breast 10. ENERGIZE | Bladder 11. CLARITY-Gastric 01 | Gastric 12. KEYNOTE-C93 | Endometrial 13. KEYNOTE-B49 | Breast 14. LITESPARK-011 | RCC 15. SigVie-002 | NSCLC 📊 The big question: Which trials will deliver meaningful survival benefits and redefine standards of care? Not every positive trial is practice-changing. 👨‍⚕️ Oncologists, which trial are you watching most closely? #ESMO26 #Oncology #CancerResearch @ASCO @oncoalert @myesmo @esmo_open